Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Roland More

Neurology The Villages, FL Medical Doctor

NPI 1437250065 CMS profile 110920

2955 Brownwood Blvd, The Villages, FL 32163

Open in the dashboard

General payments

$2,561

125 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roland More of The Villages, FL is reported in the CMS Open Payments database as having received $2,561 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $428 17
2024 General $635 26
2023 General $555 36
2022 General $229 12
2021 General $401 20
2020 General $313 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roland More
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Roland More were reported at $428. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Roland More Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $313 $367 $82–$2,309 $114
2021 $401 $438 $104–$2,547 $132
2022 $229 $442 $103–$2,388 $149
2023 $555 $464 $119–$2,312 $160
2024 $635 $468 $119–$2,323 $164
2025 $428 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $622 30 payments
  2. Amgen Inc. $298 12 payments
  3. Eisai Inc. $200 4 payments
  4. Teva Pharmaceuticals USA, Inc. $164 22 payments
  5. Lundbeck LLC $163 7 payments
  6. Genentech USA, Inc. $134 7 payments
  7. Amneal Pharmaceuticals LLC $128 7 payments
  8. Mylan Specialty L.P. $121 1 payment
  9. Lilly USA, LLC $109 6 payments
  10. Neurocrine Biosciences, Inc. $88 4 payments
  11. Other $534 25 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,561 125 payments
Products named General payments · program years 2020–2025
  1. QULIPTA $495 22 payments
  2. AIMOVIG $298 12 payments
  3. UBRELVY $249 13 payments
  4. Leqembi $200 4 payments
  5. VYEPTI $163 7 payments
  6. YUPELRI $121 1 payment
  7. EMGALITY $109 6 payments
  8. OCREVUS $107 6 payments
  9. RYTARY $105 6 payments
  10. BOTOX $96 4 payments
  11. Other $1,089 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

3,040

Median for Neurology: 833

Drug cost

$1,688,969

Median for Neurology: $202,670

Branded share of claims

34.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 35 $664,439
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 26 $286,961
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 22 $133,628
Emgality Pen Galcanezumab-Gnlm Brand 158 $125,079
Nurtec Odt Rimegepant Sulfate Brand 49 $90,134
Ubrelvy Ubrogepant Brand 52 $75,013
Aimovig Autoinjector Erenumab-Aooe Brand 72 $71,148
Qulipta Atogepant Brand 39 $55,944
Ajovy Autoinjector Fremanezumab-Vfrm Brand 30 $38,972
Abilify Maintena Aripiprazole Brand 12 $25,515

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$88,277

Of which drugs: $44,814

Medicare patients

207

Average age 76

Services billed

9,422

115 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Depression 45%
Ischemic heart disease 42%
Chronic kidney disease 36%
Diabetes 32%
Atrial fibrillation 23%
Cancer 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 9,000 $44,814

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $178
$178 — —
QULIPTA
  • AbbVie, Inc. $124
$124 39 —
UBRELVY
  • AbbVie, Inc. $51
$51 52 —
VYEPTI
  • Lundbeck LLC $49
$49 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record